Radius health, inc. announces acquisition of orphan disease program

Boston, jan. 06, 2021 (globe newswire) -- radius health, inc. (“radius” or the “company”) (nasdaq: rdus) today announced a definitive agreement to acquire the global development and commercialization rights to benuvia therapeutics inc.'s (“benuvia”) synthetic cannabidiol oral solution (“rad011”). the company plans to initiate a pivotal phase 2/3 study for patients with prader-willi syndrome (“pws”) in the second half of 2021 pending regulatory discussion with the u.s. food and drug administration (“fda”).
RDUS Ratings Summary
RDUS Quant Ranking